David Wolk, MD
Neurology · Philadelphia, PANPI 1881794337
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,325 of the $36,037 with a category attached, or 75.8%. 5 manufacturers reported payments, led by Beckman Coulter, Inc. at 39.6% of the total. 2025 is the largest year on record at $15,372, 3.2 times the $4,800 reported in 2021.
Across 13 payments — averaging $2772.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beckman Coulter, Inc.$14K
- GSK$13K
- GE HealthCare$5K
- Eli Lilly$4K
- Life Molecular Imaging Ltd$42
Across 15 payments — averaging $82,927 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.2M
- Functional Neuromodulation Inc$10K
- Merck$7K
What the payments were for
- Consulting fees$27,32576%
- Speaking & faculty fees$8,30023%
- Travel & lodging$3701%
- Food & beverage$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beckman Coulter, Inc. | 5 | $14,270 |
| GSK | 4 | $13,000 |
| GE HealthCare | 1 | $4,800 |
| Eli Lilly | 2 | $3,925 |
| Life Molecular Imaging Ltd | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DXI 9000 Access Immunoassay Analyzer$8,180
- VIZAMYL$4,800
How this compares
$36,037 in reported general payments places this provider in the 85th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 16 | $3,111 |
| Memantine Hcl ErMemantine Hcl | 24 | $1,630 |
| Donepezil Hcl | 78 | $784 |
| Olanzapine | 13 | $383 |
| Quetiapine Fumarate | 17 | $228 |
| Sertraline Hcl | 24 | $169 |
| Mirtazapine | 11 | $102 |
| Clonazepam | 30 | $77 |
| Escitalopram Oxalate | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.